CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
Liposomal Bupivicaine +1 moredrug
Likely dose
Liposomal Bupivicaine 266 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02499159
NCT02499159Phase 4Completed
CompareCT.gov

A Randomized Controlled Trial of the Effectiveness of Liposomal Bupivacaine (Exparel) When Compared to Local Injection of Bupivacaine After Thoracoscopy

Inova Health Care Services·interventional·Posted Jul 16, 2015·Updated Feb 16, 2021

In Brief

A Phase 4 clinical trial evaluating Liposomal Bupivicaine and 0.25% standard bupivicaine for Pain. Completed, enrolled 100 participants across 2 sites.

Detailed Summary

This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on decreasing the amount of consumed pain medications. Patients will be randomly selected to received either Exparel or standard bupivicaine injection during surgery. Patients will be followed up to assess pain levels using a visual pain scale, and to assess how much pain medication was consumed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
CollaboratorsMednax National Medical Group

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 16, 2015
Enrollment StartDec 1, 2014
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.0 years ago

Interventions

Liposomal Bupivicainedrug

266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.

0.25% standard bupivicainedrug

standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.